Company: MLTX
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001140361-25-014923
Chunk: 40

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 40
---
 each calendar month as described in footnote (1) above. For fiscal year 2022, the amounts have been converted to USD from CHF using the exchange rate of 1.083 USD to 1 CHF as of December 31, 2022. |

26

TABLE OF CONTENTS

2024 Grants of Plan-Based Awards Table Our named executive officers did not receive any non-equity incentive plan awards nor any equity awards in fiscal year 2024. Outstanding Equity Awards at 2024 Fiscal Year End Table The following table sets forth information regarding outstanding equity awards at the end of 2024 for each of our NEOs.

|                           |     | Stock Awards        |     |                   |     |                    |
| Name                      |     | Grant Date          |     |  Number of Shares 
 or Units of Stock 
     That Have Not 
            Vested 
            (#)(1) |     |    Market Value of 
 Shares or Units of 
    Stock That Have 
         Not Vested 
             ($)(2) |
| Dr. Jorge Santos da Silva |     | January 18, 2022(3) |     |            91,363 |     |          4,947,306 |
| Matthias Bodenstedt       |     | January 18, 2022(3) |     |           137,044 |     |          7,420,933 |
| Dr. Kristian Reich        |     | January 18, 2022(3) |     |            91,363 |     |          4,947,306 |

| (1) | Represents the number of MoonLake Immunotherapeutics Class A Ordinary Shares based on the exchange ratio of 1 share of MoonLake AG into 33.638698 MoonLake Immunotherapeutics Class A Ordinary Shares. |

| (2) | Based on the closing price of $54.15 on December 31, 2024, which was the last trading day of 2024. |

| (3) | Represents the remaining unvested portion of 10,000, 15,000 and 10,000 shares of MoonLake AG, respectively, for Drs. Santos da Silva and Reich and Mr. Bodenstedt purchased under the ESPP at a purchase price equal to the nominal value per share of CHF 0.10. Subject to the executive’s continued employment through each applicable vesting date, these shares vest in accordance with the following vesting